Shoulder Innovations Inc Dossier
Qualitative Analysis
Business overview
Shoulder Innovations, Inc. (NYSE: SI) is a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market. The company designs, develops, manufactures, and distributes advanced implant systems for shoulder arthroplasty. Its core offering is built around its proprietary, FDA-cleared InSet™ Glenoid technology, which is designed to reduce mechanical stress at the bone-implant interface, improve fixation mechanics, enhance stability, and reduce micromotion to address glenoid loosening—the primary cause of failure in shoulder arthroplasty. The company's product portfolio includes the InSet™ Total Shoulder Arthroplasty, InSet™ Reverse Shoulder Arthroplasty, InSet™ I-135RFX Humeral Stem, and the ProVoyanceu0000 AI-powered 3D preoperative planning software.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Full commercial launch of the InSet™ I-135RFX Humeral Stem, expanding the I-Series humeral stem product line to address primary, revision, and fracture total shoulder arthroplasty procedures.
Expected impact: Expands the comprehensive suite of solutions offered to shoulder specialists, driving volume growth and higher average selling prices.
Expanding the specialized commercial sales force and investing in surgeon education and training programs to accelerate market penetration.
Expected impact: Aims to onboard new surgeon customers and increase utilization rates among the estimated 1,800 high-volume shoulder specialists in the U.S.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
To develop and introduce a shoulder-specific micro-robotic solution designed to enhance surgical precision and workflow efficiency. The robotic solution will integrate with Shoulder Innovations' ProVoyance platform, targeting ambulatory surgery centers (ASCs).
Terms: Includes milestone payments and development-related expenses, which contributed to increased R&D expenses in Q4 2025 and Q1 2026.